

Davide Bimbatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522209/publications.pdf>

Version: 2024-02-01

23
papers

445
citations

840776

11
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

935
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e645-e653.	1.9	115
2	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	7.7	71
3	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	7.7	41
4	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKIs versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , 2017, 83, 237-246.	2.8	30
5	Cabozantinib-related cardiotoxicity: a prospective analysis in a <i>real-world</i> cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1283-1289.	2.4	21
6	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017, 8, 7328-7335.	1.8	19
7	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	3.6	18
8	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 112-117.	7.7	17
9	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4687-4695.	2.2	16
10	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016, 11, 569-577.	3.6	15
11	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2019, 46, 65-72.	2.2	14
12	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , 2017, 9, 579-587.	2.0	11
13	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 526.e13-526.e18.	1.6	10
14	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 269-273.	2.4	10
15	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 39-43.	1.2	8
16	Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33.	7.7	8
17	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7
18	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1037-1048.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. Journal of Onco-Nephrology, 2017, 1, 132-142.	0.6	4
20	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. Future Science OA, 2015, 1, FSO29.	1.9	2
21	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 435-435.	1.6	2
22	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 469-473.	1.4	1
23	Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 553-553.	1.6	0